TY - JOUR
T1 - Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
AU - Moskowitz, Craig H.
AU - Walewski, Jan
AU - Nademanee, Auayporn
AU - Masszi, Tamas
AU - Agura, Edward
AU - Holowiecki, Jerzy
AU - Abidi, Muneer H.
AU - Chen, Andy I.
AU - Stiff, Patrick
AU - Viviani, Simonetta
AU - Bachanova, Veronika
AU - Sureda, Anna
AU - McClendon, Teresa
AU - Lee, Connie
AU - Lisano, Julie
AU - Sweetenham, John
N1 - Funding Information:
Medical editorial assistance was provided by Ann T. Yeung (ScientificPathways, Inc.), with funding from Seattle Genetics, Inc.
Publisher Copyright:
© 2018 by The American Society of Hematology
PY - 2018/12/20
Y1 - 2018/12/20
N2 - The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). Results showed that BV significantly improved progression-free survival (PFS) vs placebo plus best supportive care alone. At 5-year follow-up, BV continued to provide patients with sustained PFS benefit; 5-year PFS was 59% (95% confidence interval [CI], 51-66) with BV vs 41% (95% CI, 33-49) with placebo (hazard ratio [HR], 0.521; 95% CI, 0.379-0.717). Similarly, patients with ‡2 risk factors in the BV arm experienced significantly higher PFS at 5 years than patients in the placebo arm (HR, 0.424; 95% CI, 0.302-0.596). Upfront consolidation with BV significantly delayed time to second subsequent therapy, an indicator of ongoing disease control, vs placebo. Peripheral neuropathy, the most common adverse event in patients receiving BV, continued to improve and/or resolve in 90% of patients. In summary consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated. Physicians should consider each patient's HL risk factor profile when making treatment decisions.
AB - The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). Results showed that BV significantly improved progression-free survival (PFS) vs placebo plus best supportive care alone. At 5-year follow-up, BV continued to provide patients with sustained PFS benefit; 5-year PFS was 59% (95% confidence interval [CI], 51-66) with BV vs 41% (95% CI, 33-49) with placebo (hazard ratio [HR], 0.521; 95% CI, 0.379-0.717). Similarly, patients with ‡2 risk factors in the BV arm experienced significantly higher PFS at 5 years than patients in the placebo arm (HR, 0.424; 95% CI, 0.302-0.596). Upfront consolidation with BV significantly delayed time to second subsequent therapy, an indicator of ongoing disease control, vs placebo. Peripheral neuropathy, the most common adverse event in patients receiving BV, continued to improve and/or resolve in 90% of patients. In summary consolidation with BV in adult patients with cHL at high risk of relapse or progression after auto-HSCT confers a sustained PFS benefit and is safe and well tolerated. Physicians should consider each patient's HL risk factor profile when making treatment decisions.
UR - http://www.scopus.com/inward/record.url?scp=85058779535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058779535&partnerID=8YFLogxK
U2 - 10.1182/blood-2018-07-861641
DO - 10.1182/blood-2018-07-861641
M3 - Article
C2 - 30266774
AN - SCOPUS:85058779535
SN - 0006-4971
VL - 132
SP - 2639
EP - 2642
JO - Blood
JF - Blood
IS - 25
ER -
